ERBB2 and cancer: Furthermore, a recent report has shown that HER2 inactivation led to the activation of NOTCH1, which in turn promoted mammary tumour dormancy and recurrence49, suggesting that NOTCH1 inhibition may have broader applications in the treatment of drug resistance in multiple human cancers.